{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:52:40Z","timestamp":1790855560318,"version":"4.1.0"},"reference-count":47,"publisher":"Impact Journals, LLC","issue":"25","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,6,21]]},"DOI":"10.18632\/oncotarget.9326","type":"journal-article","created":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T01:30:03Z","timestamp":1463103003000},"page":"37762-37772","source":"Crossref","is-referenced-by-count":122,"title":["The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells"],"prefix":"10.18632","volume":"7","author":[{"given":"Caroline","family":"Jochems","sequence":"first","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Fantini","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romaine I.","family":"Fernando","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna R.","family":"Kwilas","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee N.","family":"Donahue","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M.","family":"Lepone","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Italia","family":"Grenga","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Seung","family":"Kim","sequence":"additional","affiliation":[{"name":"Radioimmune Inorganic Chemistry Section, Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin W.","family":"Brechbiel","sequence":"additional","affiliation":[{"name":"Radioimmune Inorganic Chemistry Section, Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Gulley","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi A.","family":"Madan","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Heery","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Hodge","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Newton","sequence":"additional","affiliation":[{"name":"Incyte Corporation, Wilmington, DE, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Schlom","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwong Y.","family":"Tsang","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,5,12]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0167-5699(99)01520-0","article-title":"Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?","volume":"20","author":"Munn","year":"1999","journal-title":"Immunol Today"},{"key":"2","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1084\/jem.189.9.1363","article-title":"Inhibition of T cell proliferation by macrophage tryptophan catabolism","volume":"189","author":"Mellor","year":"1999","journal-title":"J Exp Med"},{"key":"3","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.4049\/jimmunol.164.7.3596","article-title":"Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation","volume":"164","author":"Young","year":"2000","journal-title":"J Immunol"},{"key":"4","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nature13323","article-title":"Aryl hydrocarbon receptor control of a disease tolerance defence pathway","volume":"511","author":"Volpi","year":"2014","journal-title":"Nature"},{"key":"5","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/blood-2006-07-036863","article-title":"Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells","volume":"109","author":"Massaia","year":"2007","journal-title":"Blood"},{"key":"6","doi-asserted-by":"crossref","first-page":"5396","DOI":"10.4049\/jimmunol.181.8.5396","article-title":"The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation","volume":"181","author":"Blazar","year":"2008","journal-title":"J Immunol"},{"key":"7","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood-2008-11-191197","article-title":"Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells","volume":"114","author":"Young","year":"2009","journal-title":"Blood"},{"key":"8","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.4049\/jimmunol.0903670","article-title":"An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells","volume":"185","author":"Bradfield","year":"2010","journal-title":"J Immunol"},{"key":"9","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/nm934","article-title":"Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase","volume":"9","author":"Van den Eynde","year":"2003","journal-title":"Nat Med"},{"key":"10","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1126\/science.1073514","article-title":"Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase","volume":"297","author":"Mellor","year":"2002","journal-title":"Science"},{"key":"11","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1172\/JCI21583","article-title":"Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes","volume":"114","author":"Mellor","year":"2004","journal-title":"J Clin Invest"},{"key":"12","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.2174\/092986711795656045","article-title":"Indoleamine 2,3-dioxygenase, Tregs and cancer","volume":"18","author":"Munn","year":"2011","journal-title":"Curr Med Chem"},{"key":"13","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1158\/1078-0432.CCR-05-1966","article-title":"Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells","volume":"12","author":"Fuchs","year":"2006","journal-title":"Clin Cancer Res"},{"key":"14","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s00432-008-0395-1","article-title":"Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma","volume":"134","author":"Xia","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"key":"15","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1158\/1078-0432.CCR-07-4144","article-title":"Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival","volume":"14","author":"Kikkawa","year":"2008","journal-title":"Clin Cancer Res"},{"key":"16","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/j.1349-7006.2007.00470.x","article-title":"Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer","volume":"98","author":"Saito","year":"2007","journal-title":"Cancer Sci"},{"key":"17","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/sj.bjc.6603763","article-title":"Mechanisms of local immunosuppression in cutaneous melanoma","volume":"96","author":"Cree","year":"2007","journal-title":"Br J Cancer"},{"key":"18","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1593\/neo.04658","article-title":"Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer","volume":"7","author":"Frumento","year":"2005","journal-title":"Neoplasia"},{"key":"19","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20130066","article-title":"Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4","volume":"210","author":"Allison","year":"2013","journal-title":"J Exp Med"},{"key":"20","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/0003-9861(91)90142-6","article-title":"1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase","volume":"291","author":"Sono","year":"1991","journal-title":"Arch Biochem Biophys"},{"key":"21","article-title":"A phase I study of indoximod in combination with docetaxel in metastatic solid tumors. 2013 ASCO Annual Meeting","volume":"31","author":"Link","year":"2013","journal-title":"J Clin Oncol"},{"key":"22","article-title":"Overcoming tumor antigen anergy in human malignancies using the novel indeolamine 2,3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-D-tryptophan (1MT) 2009 ASCO Annual Meeting","volume":"27","author":"Link","year":"2009","journal-title":"J Clin Oncol"},{"key":"23","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1158\/1535-7163.MCT-09-0628","article-title":"Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors","volume":"9","author":"Vaddi","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"24","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1182\/blood-2009-09-246124","article-title":"Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity","volume":"115","author":"Polam","year":"2010","journal-title":"Blood"},{"key":"25","article-title":"Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies. 2013 ASCO Annual Meeting","volume":"31","author":"Gajewski","year":"2013","journal-title":"J Clin Oncol"},{"key":"26","article-title":"Pharmacodynamic assessment of INCB024360, an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), in advanced cancer patients. 2012 ASCO Annual Meeting","volume":"2012","author":"Leopold","year":"2012","journal-title":"J Clin Oncol"},{"key":"27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00262-013-1494-7","article-title":"Identification and characterization of agonist epitopes of the MUC1-C oncoprotein","volume":"63","author":"Tsang","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"28","article-title":"Preliminary results from a phase 1\/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. 2014 ASCO Annual Meeting","volume":"32","author":"Maleski","year":"2014","journal-title":"J Clin Oncol"},{"key":"29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2051-1426-2-3","article-title":"Mechanism of tumor rejection with doublets of CTLA-4, PD-1\/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment","volume":"2","author":"Gajewski","year":"2014","journal-title":"J Immunother Cancer"},{"key":"30","doi-asserted-by":"crossref","first-page":"e6910","DOI":"10.1371\/journal.pone.0006910","article-title":"The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase","volume":"4","author":"Andersen","year":"2009","journal-title":"PLoS One"},{"key":"31","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1182\/blood-2010-06-288498","article-title":"Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators","volume":"117","author":"Andersen","year":"2011","journal-title":"Blood"},{"key":"32","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/imm.12274","article-title":"Induction of hepatitis B virus surface antigen-specific cytotoxic T lymphocytes can be up-regulated by the inhibition of indoleamine 2,3-dioxygenase activity","volume":"142","author":"Seishima","year":"2014","journal-title":"Immunology"},{"key":"33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cellsig.2009.09.013","article-title":"Induction of indoleamine 2,3-dioxygenase by death receptor activation contributes to apoptosis of melanoma cells via mitochondrial damage-dependent ROS accumulation","volume":"22","author":"Hassan","year":"2010","journal-title":"Cell Signal"},{"key":"34","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/jcb.22308","article-title":"Hemoglobin induces the expression of indoleamine 2,3-dioxygenase in dendritic cells through the activation of PI3K, PKC, and NF-kappaB and the generation of reactive oxygen species","volume":"108","author":"Nagase","year":"2009","journal-title":"J Cell Biochem"},{"key":"35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4049\/jimmunol.156.1.42","article-title":"Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites","volume":"156","author":"Hellstrand","year":"1996","journal-title":"J Immunol"},{"key":"36","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.intimp.2011.02.005","article-title":"L-kynurenine-induced apoptosis in human NK cells is mediated by reactive oxygen species","volume":"11","author":"Hur","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"37","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1189\/jlb.1103595","article-title":"Oxygen radical-induced natural killer cell dysfunction: role of myeloperoxidase and regulation by serotonin","volume":"75","author":"Hellstrand","year":"2004","journal-title":"J Leukoc Biol"},{"key":"38","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S1471-4906(03)00070-X","article-title":"Melanoma immunotherapy: a battle against radicals?","volume":"24","author":"Hellstrand","year":"2003","journal-title":"Trends Immunol"},{"key":"39","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/blood-2007-06-096081","article-title":"Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality","volume":"111","author":"Blazar","year":"2008","journal-title":"Blood"},{"key":"40","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.4049\/jimmunol.0900986","article-title":"IDO activates regulatory T cells and blocks their conversion into Th17-like T cells","volume":"183","author":"Mellor","year":"2009","journal-title":"J Immunol"},{"key":"41","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1126\/science.1078231","article-title":"Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells","volume":"299","author":"Medzhitov","year":"2003","journal-title":"Science"},{"key":"42","doi-asserted-by":"crossref","first-page":"6102","DOI":"10.1182\/blood-2008-12-195354","article-title":"Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes","volume":"113","author":"Munn","year":"2009","journal-title":"Blood"},{"key":"43","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.1158\/1078-0432.CCR-15-0420","article-title":"Molecular pathways: targeting IDO1 and other tryptophan dioxygenases for cancer immunotherapy","volume":"21","author":"Wainwright","year":"2015","journal-title":"Clin Cancer Res"},{"key":"44","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/jnci\/87.13.982","article-title":"Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine","volume":"87","author":"Schlom","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"45","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1470-2045(12)70006-2","article-title":"Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial","volume":"13","author":"Gulley","year":"2012","journal-title":"Lancet Oncol"},{"key":"46","first-page":"2439","article-title":"Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen","volume":"3","author":"Schlom","year":"1997","journal-title":"Clin Cancer Res"},{"key":"47","doi-asserted-by":"publisher","DOI":"10.5772\/62322","article-title":"Analyses of 123 peripheral human immune cell subsets: defining differences with age and between healthy donors and cancer patients not detected in analysis of standard immune cell types","volume":"5","author":"Schlom","year":"2016","journal-title":"J Circ Biomark"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.9326","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T05:53:26Z","timestamp":1692338006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.9326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,12]]},"references-count":47,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2016,6,21]]}},"alternative-id":["9326","27192116"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.9326","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,12]]}}}